Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
OBJECTIVE
To investigate the pharmacokinetics and safety of PD 0200390 in healthy subjects and subjects with renal impairment (RI) and to examine the relationship between oral and renal PD 0200390 clearance and estimated creatinine clearance (CLcr).


METHODS
In this open-label study, 26 subjects were categorized into four groups based on renal function: no RI (CLcr >80 ml min(-1); n= 6); mild RI (CLcr 51 to < or =80 ml min(-1); n= 6); moderate RI (CLcr >30 to 50 ml min(-1); n= 6); and severe RI (CLcr < or =30 ml min(-1); n= 8). Subjects received a single, oral dose of PD 0200390 25 mg. Noncompartmental pharmacokinetic parameters were determined from plasma and urine concentration-time data.


RESULTS
PD 0200390 was rapidly absorbed; mean time to maximum plasma concentration was 1.66-3.24 h. Mean half-life in subjects with normal renal function was 5.36 h, and increased with worsening RI. Oral (CL/F) and renal (CL(R)) clearance rates decreased with deteriorating renal function, whereas area under the concentration-time curve (AUC(0-infinity)) values increased by 56, 117 and 436% in subjects with mild, moderate and severe RI, respectively, indicating increased PD 0200390 exposure. Regression analysis demonstrated that CL/F and CL(R) correlated with CLcr (r= 0.953 and 0.961, respectively). PD 0200390 was well tolerated in subjects with mild, moderate or no RI. The most common adverse events were somnolence, dizziness and headache; these occurred with greatest intensity in the severe RI group.


CONCLUSIONS
PD 0200390 pharmacokinetic parameters (CL/F, CL(R) and AUC(0-infinity)) vary predictably with decreases in renal function; therefore dose adjustment may be required in individuals with RI.
Corrigan
Brian
B
Department of Neuroscience, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320, USA. brian.corrigan@pfizer.com
Feltner
Douglas E
DE
Ouellet
Daniele
D
Werth
John L
JL
Moton
Allen E
AE
Gibson
Gordon
G
D000085:Acetates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015220:Calcium Channels / Q000378:metabolism / Q000493:pharmacokinetics*; D003517:Cyclopentanes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics*; D012016:Reference Values; D012044:Regression Analysis; D012720:Severity of Illness Index; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D055815:Young Adult
C547571:(1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid; D000085:Acetates; C425903:CACNA2D1 protein, human; D015220:Calcium Channels; D003517:Cyclopentanes; D010726:Phosphodiesterase Inhibitors
Trends Pharmacol Sci. 2007 Feb;28(2):75-82
17222465
Am J Health Syst Pharm. 2006 Jan 1;63(1):41-8
16373464
Sleep. 2002 Sep 15;25(6):625-9
12224841
CNS Neurol Disord Drug Targets. 2007 Feb;6(1):3-16
17305550
Nephron. 1976;16(1):31-41
1244564
Sleep. 2007 Mar;30(3):274-80
17425223
Fundam Clin Pharmacol. 1993;7(1):1-9
8458597
Br J Psychiatry. 1997 Oct;171:382-8
9373431
Am J Psychiatry. 1997 Oct;154(10):1417-23
9326825